Hi Silsol,
https://www.jnj.com/u-s-fda-grants-priority-review-of-invokana-canagliflozin-snda-for-the-treatment-of-chronic-kidney-disease-in-patients-with-type-2-diabetes
I just copied & pasted the above, because as stated in your previous post, priority review takes about 6 months, and J&J put in their application in March 2019, so they could be looking at Sept/Oct 2019, not January 2020 as we initially anticipated, prior to their announcement regarding the FDA application.
Ann: Appendix 4C - March 2019 Quarterly Report, page-50
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
29.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $48.23M | |||
| Open | High | Low | Value | Volume |
| 30.5¢ | 30.5¢ | 29.0¢ | $171.2K | 579.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 1890 | 29.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 30.0¢ | 712 | 1 |
View Market Depth
| Last trade - 15.28pm 27/06/2025 (20 minute delay) ? |
| PIQ (ASX) Chart |